Acumen Pharmaceuticals In... (ABOS)
1.65
0.04 (2.48%)
At close: Jan 17, 2025, 3:59 PM
1.65
0.00%
After-hours Jan 17, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | n/a | n/a | n/a | 1.44M | 1.70M |
| Cost of Revenue | 42.32M | 169.00K | 4.00K | 8.00K | 8.58K |
| Gross Profit | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M |
| Operating Income | -61.14M | -45.24M | 61.57M | -7.91M | -7.80M |
| Interest Income | 10.21M | 2.39M | 84.00K | 1K | 45.00K |
| Pretax Income | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Net Income | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
| Selling & General & Admin | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Research & Development | 42.32M | 32.36M | 12.30M | 8.00M | 8.58M |
| Other Expenses | n/a | -11.00K | 51.00K | n/a | n/a |
| Operating Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Income Tax | n/a | -2.38M | 81.07M | -1K | -45.00K |
| Shares Outstanding (Basic) | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
| Shares Outstanding (Diluted) | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
| EPS (Basic) | -1.08 | -1 | -4.49 | -0.18 | -0.2 |
| EPS (Diluted) | -1.08 | -1 | -4.49 | -0.18 | -0.2 |
| EBITDA | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K |
| Depreciation & Amortization | 184.00K | 169.00K | 4.00K | 7.91M | 7.80M |